trial

Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia

NCTId NCT00611806
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 140 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2010-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
140 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-12
Primary completion
2010-08
Eligibility
ALL · 18 Years · 68 Years

Interventions & indications

Drugs
Folic AcidB12

Sponsors

Massachusetts General HospitalLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

3 total
Boston, United StatesGrand Rapids, United StatesRochester, United States

Facts & assertions

4 sourced
Enrollment
140
Phase
PHASE4
Primary Completion Date
2010-08
Status
COMPLETED
relationships
The graph out of here
drug
Folic Acid
drug
B12
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Donald C. Goff, MD
person